COGNITION THERAPEUTICS INC

Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. The company's website is www.cognitiontherapeutics.com.

The company's lead product candidate is zervimesine, also known as CT1812, an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease and dementia with Lewy bodies. Zervimesine received Fast Track designation from the U.S. Food and Drug Administration for Alzheimer's disease and was granted the USAN name zervimesine by the United States Adopted Name Council in December 2024.

Cognition Therapeutics has completed Phase 2 clinical trials for zervimesine in multiple indications. The company's COG0201 SHINE study evaluated zervimesine in mild-to-moderate Alzheimer's disease with 153 participants, while the ongoing COG0203 START Phase 2 study is evaluating the drug in patients with mild cognitive impairment and early-stage Alzheimer's disease across 545 participants. The company also completed the COG1201 SHIMMER Phase 2 study in 130 adults with mild-to-moderate dementia with Lewy bodies and initiated an expanded access program for DLB patients in June 2025. A Phase 2 study in geographic atrophy secondary to dry age-related macular degeneration was voluntarily concluded in January 2025.

The company's clinical trials have been funded by approximately $171 million in cumulative grants awarded primarily by the National Institute of Aging, a division of the National Institutes of Health. As of October 2025, approximately 782 subjects have received zervimesine across the company's clinical programs. Cognition Therapeutics retains worldwide rights to zervimesine for all indications and intends to pursue development and approval in major markets while exploring strategic collaborations and partnerships to maximize commercial potential.